In SSc derived PBMCs, neutralizing IL-17A antibodies significantly decreased the synthesis of FGF2 (8.29±2.3 vs 15.77±5.18 pg/ml) and relative mRNA levels (from 2,4-fold to 0,89-fold compared to untreated control, p<0.01); conversely IL-17A inhibition significantly enhanced the synthesis and mRNA expression of TFGβ (891.53±22.5 vs 784.12±239.6 pg/ml p<0.01, relative mRNA levels from 1.4-fold to 1.9-fold, p<0.05) and CTGF (117.29±16.6 vs 105.2±14.1 pg/ml, relative mRNA levels from 1.62-fold to 2.01-fold, p<0.05). This evidence concerns the gene IL17A and systemic sclerosis.